Physician profile
Jerald Goldstein
NPI 1770569626
$10,939.89
in general payments reported to CMS, 2019-2025
11 companies · $603 in 2025
The $603 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $162 · 2021: $423 · 2022: $7,671 · 2023: $218 · 2024: $348 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150 · Debt Forgiveness: $19.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.63 |
| Debt Forgiveness | $19.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $9,192.30 | 2019-2025 | Menopur |
| Coopersurgical, INC. | $565.65 | 2020-2025 | Stripper |
| Emd Serono, INC. | $429.06 | 2020-2023 | |
| Organon LLC | $368.83 | 2021-2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Vitrolife INC. | $169.66 | 2019-2023 | |
| Hologic Sales and Service, LLC | $64.05 | 2025 | Aptima |
| Novo Nordisk INC | $59.86 | 2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $41.51 | 2020 | |
| Myovant Sciences INC. | $22.50 | 2021 | |
| Minerva Surgical, INC | $15.56 | 2024 | |
| Galen US INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.